Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
Holding URGN?
Track your performance easily
URGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.60 - $20.70
Previous Close$13.54
Volume1.22M
Average Volume (3M)522.36K
Market Cap
$570.22M
Enterprise Value$427.38M
Total Cash (Recent Filing)$241.08M
Total Debt (Recent Filing)$98.24M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 12, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding42,114,070
10 Day Avg. Volume669,575
30 Day Avg. Volume522,357
Standard Deviation0.24
R-Squared0.06
Alpha-0.00422
Financial Highlights & Ratios
Price to Book (P/B)18.81
Price to Sales (P/S)6.71
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.03
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda-4.72
Forecast
1Y Price Target
$40.50Price Target Upside199.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Urogen Pharma News
PremiumCompany Announcements
UroGen Pharma Reports Q3 Results and Drug Progress
PremiumCompany Announcements
UroGen Pharma Announces CFO Transition and Compensation Details
Bulls Say, Bears Say
Bulls Say
EarningsUroGen closed 2Q24 with ~$241M in cash and short-term investments; the company believes it may be able to reach profitability without requiring further equity dilution.
Market PotentialThe target market for UGN-102 may be >$5B annually—far larger than the JELMYTO market.
Product ApprovalUroGen announced the successful completion of its New Drug Application (NDA) submission to the FDA for approval of UGN-102 for intravesical solution, a significant advance in potentially addressing the urgent need for innovative treatments for low-grade intermediate-risk non-muscle invasive bladder cancer.
Bears Say
Financial PerformanceFinancial results reported—top- and bottom-line miss, reduced near-term revenue outlook.
Market PositionCautious on UGN-102’s ability to displace TURBT surgery as the standard of care in the near term, which is entrenched as a longstanding urologist practice.
SalesJelmyto sales flat y/y as focus remains on completing the rolling NDA submission for UGN-102.
---
Ownership Overview
8.83% Insiders
2.50% Mutual Funds
65.78% Other Institutional Investors
22.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $10.60 and its highest was $20.70 in the past 12 months.
What is Urogen Pharma’s market cap?
Currently, no data Available
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 12, 2024 which is 15 days ago.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 13, 2024. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.832 by -$0.078.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -$0.83.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 42,114,070 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.832. Following the earnings report the stock price went up 3.101%.
Which hedge fund is a major shareholder of Urogen Pharma?
Among the largest hedge funds holding Urogen Pharma’s share is RA Capital Management. It holds Urogen Pharma’s shares valued at 52M.
---
Urogen Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.50 (199.11% Upside)
$40.50 (199.11% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 274.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
195.56%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.
---
URGN Earnings Call
Q2 2024
0:00 / 0:00
---
URGN Stock 12 Month Forecast
Average Price Target
$40.50
▲(199.11% Upside)
Technical Analysis
Kala Pharmaceuticals
―
Fennec Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering URGN
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+13.41%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +13.41% per trade.
---